New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC
|New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC|
J Clin Oncol. 2021;39:suppl 9014.
Ramalingam SS, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.